title: A focus on PD-L1 in human melanoma.
abstract: Treatment of metastatic melanoma with inhibitors of the BRAF V600 oncogene in melanoma has been limited by the development of resistance. Combining the BRAF inhibitors with immunotherapy may prolong the response, but will acquisition of resistance to BRAF inhibitors also make melanoma cells resistant to immunotherapy?
authors.affiliation: Kolling Institute, Royal North Shore Hospital & Melanoma Institute of Australia, University of Sydney, New South Wales, Australia. peter.hersey@sydney.edu.au
authors.forename: Peter
authors.initials: P
authors.lastname: Hersey
authors.forename: Stuart
authors.initials: S
authors.lastname: Gallagher
mesh_terms: D060890:B7-H1 Antigen / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008545:Melanoma / Q000378:metabolism*; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D048493:Proto-Oncogene Proteins B-raf / Q000378:metabolism*
chemical_list: D060890:B7-H1 Antigen; C423236:CD274 protein, human; D047428:Protein Kinase Inhibitors; D019869:Phosphatidylinositol 3-Kinases; D048493:Proto-Oncogene Proteins B-raf; D020929:Mitogen-Activated Protein Kinase Kinases